BR0012757A - Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas - Google Patents

Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas

Info

Publication number
BR0012757A
BR0012757A BR0012757-4A BR0012757A BR0012757A BR 0012757 A BR0012757 A BR 0012757A BR 0012757 A BR0012757 A BR 0012757A BR 0012757 A BR0012757 A BR 0012757A
Authority
BR
Brazil
Prior art keywords
conjugates
processes
well
biological membranes
production
Prior art date
Application number
BR0012757-4A
Other languages
English (en)
Inventor
Eugen Uhlmann
Beate Greiner
Eberhard Unger
Gislinde Gothe
Marc Schwerdel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0012757A publication Critical patent/BR0012757A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)

Abstract

Patente de Invenção: "CONJUGADOS E PROCESSOS PARA PRODUçãO DOS MESMOS, BEM COMO SEU USO PARA TRANSPORTE DE MOLéCULAS ATRAVéS DE MEMBRANAS BIOLóGICAS". Objetivo da presente invenção são conjugados, processos para produção dos mesmos e o uso desses conjugados para transporte de compostos de baixa molecularidade e macromoléculas através de membranas biológicas, particularmente, para transporte de moléculas em células. Objetivo da presente invenção são também medicamentos e agentes de diagnóstico, bem como kits de teste, nos quais esses conjugados estão presentes ou são usados.
BR0012757-4A 1999-07-28 2000-07-20 Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas BR0012757A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19935302A DE19935302A1 (de) 1999-07-28 1999-07-28 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
PCT/EP2000/006936 WO2001008707A2 (de) 1999-07-28 2000-07-20 Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen

Publications (1)

Publication Number Publication Date
BR0012757A true BR0012757A (pt) 2002-04-02

Family

ID=7916258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012757-4A BR0012757A (pt) 1999-07-28 2000-07-20 Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas

Country Status (33)

Country Link
US (1) US8420396B2 (pt)
EP (1) EP1204430B1 (pt)
JP (1) JP4791665B2 (pt)
KR (1) KR100721696B1 (pt)
CN (1) CN1227035C (pt)
AR (1) AR029385A1 (pt)
AT (1) ATE447413T1 (pt)
AU (1) AU776114B2 (pt)
BR (1) BR0012757A (pt)
CA (1) CA2377977C (pt)
CY (1) CY1109744T1 (pt)
CZ (1) CZ2002300A3 (pt)
DE (2) DE19935302A1 (pt)
DK (1) DK1204430T3 (pt)
EE (1) EE05303B1 (pt)
ES (1) ES2335741T3 (pt)
HK (1) HK1047042A1 (pt)
HR (1) HRP20020074B1 (pt)
HU (1) HUP0201995A3 (pt)
IL (2) IL147527A0 (pt)
ME (1) MEP56408A (pt)
MX (1) MXPA01013114A (pt)
NO (1) NO334155B1 (pt)
NZ (1) NZ516838A (pt)
PL (1) PL202881B1 (pt)
PT (1) PT1204430E (pt)
RS (2) RS20100249A (pt)
RU (1) RU2275936C2 (pt)
SI (1) SI1204430T1 (pt)
SK (1) SK287654B6 (pt)
TR (4) TR201109491T2 (pt)
WO (1) WO2001008707A2 (pt)
ZA (1) ZA200200657B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US20070167388A1 (en) * 2003-09-11 2007-07-19 Universitätsklinikum Schleswig-Holstein Campus Lübeck Nucleotide sequences promoting the trans-membrane transport of nucleic acids
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
EP1886681A3 (en) * 2004-10-07 2008-11-19 Sulfidris S.r.l. 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione valproate ester
KR100690199B1 (ko) * 2006-04-20 2007-03-12 이화여자대학교 산학협력단 구리 이온 선택성을 갖는 플루오레세인 유도체, 이의제조방법 및 이를 이용한 생체 내 구리 이온 검출방법
RU2010112771A (ru) * 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
ES2605990T3 (es) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
SG11201608880VA (en) 2014-05-23 2016-11-29 Genzyme Corp Multiple oligonucleotide moieties on peptide carrier
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
EP3493855A4 (en) 2016-08-02 2020-04-01 ISI Life Sciences, Inc. METHOD FOR DETECTION OF CANCER CELLS.
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
US10539567B2 (en) * 2017-05-15 2020-01-21 Indicator Systems International, Inc. Biopsy methods and devices
KR20230096856A (ko) 2021-12-22 2023-06-30 한국과학기술연구원 신규 펩타이드-올리고뉴클레오티드 접합체 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801070D0 (sv) 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6228982B1 (en) 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
IL104461A (en) 1992-01-22 2001-05-20 Hoechst Ag Analogs of oligonucleotide, their preparation and pharmaceutical preparations containing them
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
WO1998020887A1 (en) * 1996-11-14 1998-05-22 Brigham And Women's Hospital, Inc. Polyphosphoinositide binding peptides for intracellular drug delivery
GB9809084D0 (en) 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
DE19824535A1 (de) * 1998-06-03 1999-12-09 Roche Diagnostics Gmbh Neue Rhodamin-Derivate und deren Verwendung
US6335432B1 (en) 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
AU5376500A (en) 1999-06-17 2001-01-09 Universiteit Gent Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application

Also Published As

Publication number Publication date
IL147527A (en) 2006-08-01
IL147527A0 (en) 2002-08-14
DE50015781D1 (de) 2009-12-17
MXPA01013114A (es) 2002-06-04
TR201109493T2 (tr) 2012-03-21
PL202881B1 (pl) 2009-07-31
JP2003505517A (ja) 2003-02-12
SK1172002A3 (en) 2002-08-06
ES2335741T3 (es) 2010-04-05
DK1204430T3 (da) 2010-03-29
ZA200200657B (en) 2003-09-23
WO2001008707A3 (de) 2001-11-08
AU776114B2 (en) 2004-08-26
SK287654B6 (sk) 2011-05-06
CA2377977A1 (en) 2001-02-08
TR200706709T2 (tr) 2008-02-21
RS51447B (sr) 2011-04-30
HRP20020074B1 (en) 2011-01-31
EP1204430A2 (de) 2002-05-15
NO334155B1 (no) 2013-12-23
YU90301A (sh) 2004-05-12
CZ2002300A3 (cs) 2002-05-15
HUP0201995A3 (en) 2005-02-28
RU2275936C2 (ru) 2006-05-10
CN1227035C (zh) 2005-11-16
EP1204430B1 (de) 2009-11-04
KR20020031392A (ko) 2002-05-01
AR029385A1 (es) 2003-06-25
JP4791665B2 (ja) 2011-10-12
WO2001008707A2 (de) 2001-02-08
NO20020367D0 (no) 2002-01-23
CN1360507A (zh) 2002-07-24
US20080071069A1 (en) 2008-03-20
SI1204430T1 (sl) 2010-03-31
HRP20020074A2 (en) 2005-10-31
CA2377977C (en) 2011-09-20
HK1047042A1 (en) 2003-02-07
TR200200222T2 (tr) 2002-07-22
ATE447413T1 (de) 2009-11-15
TR201109491T2 (tr) 2012-02-21
RS20100249A (en) 2011-02-28
NZ516838A (en) 2004-07-30
PT1204430E (pt) 2010-01-26
HUP0201995A2 (en) 2002-10-28
KR100721696B1 (ko) 2007-05-28
MEP56408A (en) 2011-05-10
PL353069A1 (en) 2003-10-06
US8420396B2 (en) 2013-04-16
NO20020367L (no) 2002-03-26
EE05303B1 (et) 2010-06-15
EE200200035A (et) 2003-04-15
DE19935302A1 (de) 2001-02-08
CY1109744T1 (el) 2014-09-10
AU6825200A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
BR0012757A (pt) Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
BRPI0517843A (pt) compostos de moléculas conjugadas com a atividade de absorção de células aumentada
BRPI0307117B8 (pt) amidas de ácido antranílico e seus derivados, bem como seus usos como compostos ativos cosméticos e farmacêuticos
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
DE69837613D1 (de) J-kette und analoge für konjugate zielgerichtet auf epithelzellen
DE50014571D1 (de) Träger-pharmaka-konjugate
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
DE69838147D1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
BR9801652A (pt) Resorcinil-triazinas
BR0107770A (pt) Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas
ATE279147T1 (de) Vielseitige hydrophile farbstoffe
Manchineella et al. Radical‐scavenging antioxidant cyclic dipeptides and silk fibroin biomaterials
DE60239729D1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BRPI0415285A (pt) derivados de aminoalcanol
TR200103004T2 (tr) Pirolidinkarbonilamino siklik disülfitler.
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
BRPI0012329B8 (pt) derivados de benzofurano, processo para sua preparação e uso dos mesmos.
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
BRPI0508895A (pt) formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico
PL373511A1 (en) Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2315 DE 19-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: C07H 21/00 (2006.01), A61K 47/54 (2017.01), C12N 1